MannKind Corp (MNKD) reports a 37% revenue increase, driven by Tyvaso DPI and Afrezza, while navigating market challenges and ...

MannKind (NASDAQ: MNKD) Q3 2024 Earnings Call Nov 07, 2024, 4:30 p.m. ET ...

Q3 2024 Earnings Call Transcript November 7, 2024 MannKind Corporation beats earnings expectations. Reported EPS is $0.05, ...

MannKind will host a conference call and presentation webcast to discuss these results today at 4:30 p.m. Eastern Time. The webcast will be accessible via a link on MannKind’s website. A replay will ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsMichael Castagna - CEOChris Prentiss ...

MannKind Corporation ( (MNKD) ) has released its Q3 earnings. Here is a breakdown of the information MannKind Corporation presented to its ...

Westlake Village-based MannKind saw rising revenue and gave a positive update to its orphan lung pipeline when it announced its earnings for the third quarter of 2024. MannKind, a biotechnology ...

Shares of MannKind Co. (NASDAQ:MNKD – Get Free Report) have received a consensus recommendation of “Buy” from the seven ...

International Assets Investment Management LLC boosted its stake in shares of MannKind Co. (NASDAQ:MNKD – Free Report) by 511 ...

It also needs to make a success of inhaled insulin Afrezza, which the company licensed from MannKind last year to bolster its diabetes franchise, although some analysts have suggested it might be ...

Afrezza. Around the same time, positive results from a study published in JMIR Diabetes demonstrated a 1.1% to 1.3% absolute reduction in HbA1c levels among One Drop Mobile users after four months ...